Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional MR (The COAPT Trial)
The purpose of this study is to compare the performance of the study device plus optimal drug therapy, to optimal drug therapy alone. The study involves functional mitral regurgitation (MR), where the two leaflets, or flaps, of the mitral valve in the heart do not close properly causing blood to leak backward every time the heart beats.
Mitral valve (MR) regurgitation
Men and women aged 18+ who have MR
have symptoms due to heart failure despite being treated with currently available therapies
are not appropriate candidates for mitral valve surgery.
18 - 99
Healthy Volunteers Needed
Duration of Participation
This study requires about 11 visits to the clinic and will take about 5 years to complete.
Evalve, Inc. (a subsidiary of Abbott Vascular)
Subjects will be compensated by OHSU up to $100 per study visit. Subjects may also be eligible for up to $125 per visit for lodging.